# Agilent Technologies, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Agilent Technologies, Inc).

## Overview

Agilent Technologies, Inc. designs and sells laboratory instruments and related consumables, software, and services used to analyze biological and chemical samples across research, diagnostics, and applied testing labs. The company is organized around three reportable segments: Life Sciences and Diagnostics Markets (including liquid chromatography and LC/MS platforms), Agilent CrossLab (services, consumables, lab automation, and informatics tied to the installed base), and Applied Markets (including gas chromatography/GCMS, spectroscopy, vacuum, and remarketed instruments). Its business model blends capital equipment sales with recurring revenue from service contracts, repair/compliance services, and consumables that support day-to-day lab operations. Agilent also refurbishes and resells certified pre-owned instruments to serve value-oriented customers and broaden access to its installed base.

## Products & services

• Liquid chromatography and LC/MS instruments and workflows
• Gas chromatography and GC/MS, spectroscopy and vacuum products
• Lab consumables, chemistries and supplies for routine testing
• Services: repair, maintenance, compliance and installation
• Lab automation systems for sample prep and throughput
• Software and informatics for instrument control and data
• Certified pre-owned (remarketed) analytical instruments

- **Life Sciences and Diagnostics Markets** (45%) — LC/LCMS platforms and related solutions used in pharma, biopharma, research and clinical/diagnostics workflows.
- **Agilent CrossLab** (35%) — Recurring services, consumables, lab automation, and software/informatics supporting the installed base.
- **Applied Markets** (20%) — GC/GCMS, spectroscopy, vacuum and remarketed instruments used in environmental, food, chemicals and forensics testing.

- Liquid chromatography and LC/MS instruments and workflows
- Gas chromatography and GC/MS, spectroscopy and vacuum products
- Lab consumables, chemistries and supplies for routine testing
- Services: repair, maintenance, compliance and installation
- Lab automation systems for sample prep and throughput
- Software and informatics for instrument control and data
- Certified pre-owned (remarketed) analytical instruments

## Customers

Agilent sells primarily to laboratories that need regulated, high-uptime analytical workflows, spanning pharmaceutical and biopharmaceutical companies, life science research organizations, and clinical/diagnostics labs. It also serves applied testing end markets such as environmental and forensics, food testing, and chemicals and advanced materials, where customers value method performance, reliability, and compliance documentation. The company uses a multi-channel go-to-market model combining direct sales for large strategic accounts with distributors, resellers, e-commerce, and manufacturers' representatives to broaden coverage. A meaningful portion of demand is tied to customers’ capital expenditure cycles for instruments, while CrossLab’s repair/maintenance services and consumables provide more recurring, installed-base-driven purchasing behavior.

- **Pharmaceutical and biopharmaceutical companies** (primary) — Buy LC/LCMS and other analytical platforms plus service contracts and consumables to support regulated QC and R&D workflows.
- **Life science research organizations** (secondary) — Purchase instruments, software/informatics and consumables for discovery and analytical characterization across lab workflows.
- **Diagnostics and clinical laboratories** (secondary) — Adopt validated analytical solutions and ongoing service to maintain uptime and compliance in clinical/diagnostic settings.
- **Applied testing labs (environmental, food, forensics)** (secondary) — Use GC/GCMS, spectroscopy and related consumables/services for routine, standards-driven testing and reporting.
- **Chemicals and advanced materials customers** (emerging) — Buy applied-market instruments and recurring consumables/services to support materials characterization and process analytics.

- Pharma and biopharma labs buying LC/LCMS and compliance services
- Clinical and diagnostics labs needing validated workflows and uptime
- Environmental and forensics labs focused on regulated testing methods
- Food testing labs purchasing consumables, automation and service
- Chemicals and advanced materials labs using GC/GCMS and spectroscopy
- Value-oriented customers purchasing certified pre-owned instruments
- Smaller accounts reached via distributors/resellers and e-commerce

## Geography

Agilent operates globally and sells across the Americas, Europe, and Asia Pacific, with demand influenced by regional research funding, industrial activity, and customer capital spending. The company’s Applied Markets manufacturing footprint includes a U.S. facility in Delaware and international manufacturing in Australia, China, Italy, Malaysia, and Singapore, supporting proximity to customers and supply chain resilience. Management commentary highlights that CrossLab is diversified across regions, which helps hedge localized weakness, but results remain exposed to foreign currency movements. Regional performance can differ by end market mix (e.g., installation and automation softness versus steady repair/maintenance and consumables demand).

- Global sales footprint across Americas, Europe and Asia Pacific
- Manufacturing in the U.S. (Delaware) supports domestic supply needs
- Manufacturing outside U.S.: Australia, China, Italy, Malaysia, Singapore
- CrossLab positioned as regionally diversified to hedge local weakness
- Foreign currency movements can meaningfully affect reported growth
- Regional mix shifts (services vs instruments) drive performance differences

## Strategy

Agilent’s current direction emphasizes a market-focused structure built around three segments, aligning product platforms and customer workflows while centralizing recurring offerings (services, consumables, automation, and informatics) within CrossLab. The company is investing in capacity expansion for nucleic acid-based therapeutics manufacturing in Frederick, Colorado, indicating a push to support growth areas tied to advanced therapeutics supply chains. CrossLab’s strategy prioritizes growing the installed-base monetization through repair, compliance, and maintenance services and by improving customer experience via digital and remote capabilities. Across segments, the company aims to compete on instrument performance and reliability while using global channel coverage and applications expertise to win and retain accounts.

- **Scale nucleic acid-based therapeutics manufacturing capacity** (medium-term) — Adds capacity in a growth area and supports customers' advanced therapeutics needs.
- **Increase installed-base monetization through CrossLab recurring offerings** (short-term) — Services and consumables are mostly recurring and less cyclical than instruments, supporting resilience.
- **Improve service delivery via digital and remote capabilities** (short-term) — Enhances customer experience and service quality while supporting efficient scaling across regions.

- Operate with a market-focused structure across three reportable segments
- Expand manufacturing capacity for nucleic acid-based therapeutics (CO)
- Grow recurring CrossLab revenue from installed base services/consumables
- Invest in digital and remote capabilities to improve service experience
- Use multi-channel sales (direct, e-commerce, distributors, resellers) to scale
- Compete on performance, reliability, applications expertise and support quality

## Risks

Demand for Agilent’s instruments is sensitive to macroeconomic conditions and customers’ capital expenditure cycles, which can lengthen sales cycles, increase cancellations, and create price pressure. The company also faces inventory risks (excess and obsolescence) when end-market demand slows or product mix shifts, particularly for configurable instrument platforms. Acquisition execution is a meaningful company-specific risk: integrating acquired businesses can increase systems complexity, raise compliance burdens, and delay expected synergies or margin targets. Like peers in analytical instruments, Agilent operates in intensely competitive markets where performance, reliability, applications support, and price can shift share and compress margins, while foreign currency movements can distort reported growth across regions.

- **General economic conditions may adversely affect operating results** [high] — Slower growth, higher rates and inflation can reduce demand, extend sales cycles, increase cancellations and price pressure, and raise inventory and impairment risks.
- **End-market declines or slower-than-expected growth** [high] — If pharma, chemicals/materials or other served markets weaken, instrument demand and related software/installation can fall, pressuring results.
- **Acquisition integration and synergy realization risk** [medium] — Integrating different cultures, systems and controls can be costly and time-consuming; synergies may be delayed or not achieved, impacting margins and reporting obligations.

- Macroeconomic weakness can reduce demand and lengthen sales cycles
- Customer capex pressure can drive order delays and cancellations
- Inventory excess/obsolescence risk if demand slows or mix changes
- Price pressure in competitive analytical instrument markets
- Acquisition integration risk (systems complexity, culture, controls)
- Failure to realize acquisition synergies on expected timeline
- Foreign currency movements can negatively impact reported growth

## Accounting

Agilent identifies revenue recognition as a critical accounting policy because it sells combinations of products (hardware/software) and services (one-time events and services performed over time), requiring judgment in identifying performance obligations and timing of recognition. Inventory valuation is also critical given the mix of configurable instruments built to order and standard products built to stock, which can increase exposure to excess and obsolete inventory reserves when demand shifts. Goodwill and purchased intangible asset valuation requires estimates and periodic impairment assessment, which can be sensitive to changes in growth expectations and discount rates, particularly after acquisitions. Retirement and post-retirement benefit plan assumptions and income tax accounting involve management estimates that can materially affect reported expense and liabilities.

- **Revenue recognition (contracts with products and services)** — Can shift revenue between quarters and between product vs service lines
- **Inventory valuation** — Affects gross margin via write-downs and reserve adjustments
- **Goodwill and purchased intangible assets** — Potential non-cash impairment charges and amortization profile
- **Retirement and post-retirement benefit plan assumptions** — Impacts operating expenses and balance sheet liabilities
- **Income taxes** — Affects effective tax rate and tax-related balance sheet accounts

- Revenue recognition for bundled instruments, software and services
- Judgment on point-in-time vs over-time service revenue recognition
- Inventory valuation and reserves for excess/obsolete inventory
- Goodwill and purchased intangible asset valuation and impairment risk
- Retirement and post-retirement benefit plan assumptions
- Income tax accounting and uncertain tax positions

---

*Last updated: 2026-09-24T11:40:52.136170+00:00*